InKemia

What InKemia does

InKemia IUCT Group is a Spain-based technology holding company founded in 1997, headquartered in Mollet del Vallès (Barcelona), and publicly listed on Spain's Mercado Alternativo Bursátil (MAB) under the ticker 1NKEMIA. The group operates three core service lines through its IUCT division: Open R&D + Innovation (custom research and development services for external companies), Technological Services (analytical and quality control services for pharmaceutical, chemical, biotech, cosmetic, and food sectors), and Training programs. The group maintains proprietary green chemistry assets including a library of 200+ green solvents, patented second-generation biodiesel technology (IUCT-S50), 67 granted patents (with US-protected metal degreasing patents valid until 2028), and a Knowledge Capital Fund (Fondo Capital Conocimiento) with minority stakes in approximately a dozen life sciences companies.

The company's technology foundation spans biocatalysis, industrial biotechnology, plant cell culture technology, and green chemistry process design. Notable proprietary platforms include Mind the Byte, a cloud-based SaaS for computational drug design and bioinformatics, and AMMIC, a rare disease drug accelerator developed with VHIR and Esteve. InKemia holds EU pharmaceutical and cosmetic import authorization (since 2012), ISO 17025 accreditation, and the Generalitat de Catalunya TECNIO seal. The group also operates wholly-owned subsidiaries Micro-Bios and Otec Riera (Spanish laboratory testing, acquired 2017), InKemia Brasil (2014), and InKemia Green Chemicals USA (2016) with Paul Anastas, the recognized father of green chemistry, as Chairman of the Scientific Council.

Revenue is generated primarily through project-based B2B services to enterprise clients in pharmaceutical, chemical, biotech, cosmetic, and food industries, with geographic operations across Spain (3 offices: Mollet del Vallès, Madrid, Vilanova i la Geltrú), Brazil, Colombia, and the USA. Distribution is via direct enterprise field sales, supplemented by participation in major industry events such as Biospain and Expoquimia. The company also generates returns from its Knowledge Capital Fund equity stakes in portfolio companies including Vytrus Biotech, Plasmia Biotech, Mind the Byte, Lean Bio, Myogem Health, Pharmamel, Bioo, Abouit, Aromics, and Cimer. Reported 2017 financials include +139% revenue growth, +25% operating income growth, and +8% EBITDA growth versus the prior year.

Name

InKemia

Legal name

Inkemia, S.A.

Website

https://inkemia.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

InKemia IUCT Group is a Spain-based, MAB-listed technology holding company providing custom R&D, analytical services, training, and green chemistry solutions to pharmaceutical, chemical, biotech, cosmetic, and food enterprises across Spain, Brazil, Colombia, and the USA.

Ownership category

akta.pro rank

Product category

Contract Research and Green Chemistry Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAGAIAI

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

SECONDARYHLAGAKAL

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

SECONDARYHLAGAKAA

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

• Green chemistry services
• Custom pharmaceutical R&D
• Analytical laboratory testing
• Biotechnology development
• Drug discovery platform

Headquarters

HQ city

Mollet del Vallès

HQ country

Spain

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Open R&D + Innovation Services: Custom research and development services for external companies, including process optimization, green chemistry applications, and new product development. Revenue generated through project-based contracts with pharmaceutical, chemical, and cosmetic companies.
2. Technological Services: Analysis and control services for pharmaceutical, chemical, cosmetic, and food industries. Includes quality control, regulatory testing, and certification services. IUCT is authorized as pharmaceutical laboratory and import laboratory in the EU since 2012.
3. Training Services: Professional training programs including Master in Pharmaceutical Industry Management (with EADA), validation of analytical methods courses, and customized corporate training. Offered both in Spain and internationally (Colombia, Latin America).
4. Knowledge Fund Investments: Investment returns from the Fondo Capital Conocimiento through equity stakes in portfolio companies. Companies include Vytrus Biotech, Plasmia Biotech, Mind the Byte, Lean Bio, Myogem Health, Pharmamel, and others.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

InKemia IUCT group generates, manages, and exploits high-technology-value knowledge through custom research and development services (OpenR&D + Innovation), technological analysis and quality control services, and professional training for the pharmaceutical, chemical, cosmetic, biotechnological, and food industries. Its portfolio includes proprietary green chemistry technologies (200+ green solvent library, IUCT-S50 biodiesel), the Mind the Byte cloud drug-discovery SaaS, EU pharmaceutical and cosmetic import authorization services, and a Knowledge Capital Fund holding minority stakes in roughly a dozen biotech portfolio companies.

Product overview

InKemia is a technology and knowledge transfer group that operates as a holding company with a portfolio of businesses in the life sciences sector. Its core operations are organized around IUCT (the knowledge division), which provides OpenR&D + Innovation (custom research services), Technological Services (analysis and quality control), and Training programs, serving the pharmaceutical, chemical, biotechnology, cosmetic, and food industries. InKemia complements its service offering with a green chemistry portfolio (IUCT-S50 second-generation biodiesel, a library of 200+ green solvents) and a cloud-based SaaS drug discovery platform (Mind the Byte). The group also operates an import authorization service for pharmaceuticals and cosmetics into the EU, pre-clinical regulatory studies for oncology drugs, and participates in rare disease drug development through the AMMIC accelerator and the EU-funded GRAIL advanced biofuels project. InKemia holds ISO 17025 accreditation and EU pharmaceutical import authorization, and manages a Knowledge Capital Fund that holds stakes in approximately a dozen biotech spin-offs.

Differentiator

Problem solved

Functional benefit

Products and services

• OpenR&D + Innovation (Custom R&D Services) Custom research and development services offered to external companies, providing tailored innovation solutions including process optimization, green chemistry applications, and new product development for pharmaceutical, chemical, cosmetic, biotech, and food industries.
• Technological Services (Analysis and Quality Control) Technology services including analysis, quality control, regulatory testing, and certification services for pharmaceutical, chemical, biotech, cosmetic, and food industries. Authorized as EU pharmaceutical import laboratory since 2012.
• Training Services (Formación) Professional training programs including the Master in Pharmaceutical Industry Management (joint with EADA), analytical method validation courses, and customized corporate training delivered in Spain and internationally (Colombia, Latin America).
• IUCT-S50 Second-Generation Biodiesel Patented second-generation biodiesel developed by IUCT as part of its green chemistry portfolio, featuring a proprietary production process.
• Green Solvents Library (Biblioteca de Disolventes Verdes) Proprietary library of more than 200 green solvents for industrial applications including pharmaceutical synthesis, metal degreasing, and paint formulations, derived from renewable raw materials.
• Green Chemistry Solutions Comprehensive green chemistry services including industrial applications of green solvents, azo pigment synthesis free of PCBs, biotechnological menadione (Vitamin K) synthesis, industrial antioxidants and preservatives, and Friedel-Crafts acylations for active pharmaceutical ingredients.
• Mind the Byte SaaS Platform Cloud-based Software as a Service platform for computational drug design and bioinformatics, offering on-demand scientific data analysis tools that reduce drug development time and cost by up to 30%.
• Pharmaceutical Import Services EU pharmaceutical import laboratory services including quality control, batch certification, and Qualified Person release for products manufactured in third countries.
• Cosmetic Import Services Services for importing cosmetics into the EU, including responsible person designation, CPNP notification, labeling review, quality control, and declaration management before AEMPS.
• Pre-Clinical Regulatory Studies Regulatory pre-clinical studies for potential oncological drugs, including the approved R&D project for pre-clinical regulatory trials.
• AMMIC — Rare Disease Drug Accelerator Accelerator for rare disease drug development led by IUCT with participation from VHIR and Esteve, addressing 7,000–8,000 rare diseases affecting over 300,000 people in Catalonia.
• Fondo Capital Conocimiento (Knowledge Capital Fund) Investment fund that manages equity stakes in a portfolio of participating companies in the life sciences and biotechnology sectors, including Vytrus Biotech, Plasmia Biotech, Mind the Byte, Lean Bio, Myogem Health, Pharmamel, Bioo-Arkyne, and others.
• GRAIL Project (Advanced Biofuels) European Union-funded project 'Glycerol Biorefinery Approach for the Production of High Quality Products of Industrial Value' converting residual glycerol from the biodiesel industry into advanced biofuels, industrial products, and food supplements, involving 15 international partners.

Quantifiable outcome

• Reduces drug development time by 1-3 years
• +2 more outcomes

Segments5 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• GC2 (Gestão do Conhecimento Científico)coreStrategic or Co-development Partner · 19 August 2016Brazilian company GC2, a central laboratory for pre-clinical and clinical research based in São Paulo, entered into collaboration with InKemia to offer pharmaceutical industry comprehensive clinical development services across Europe, Brazil, and Latin America. The partnership was later extended to include Recerca Clínica.
• Universidad de los AndescoreStrategic or Co-development Partner · 1 January 2015Framework collaboration agreement for academic activities, research, technological development, innovation, and outreach programs. Universidad de los Andes ranks first in Colombia and seventh in Latin America according to QS World University Rankings 2015.
• Barcelona BiosciencecoreStrategic or Co-development PartnerCollaboration agreement making IUCT the principal supplier for Barcelona Bioscience. Two co-development projects initiated: one focused on psoriasis and another on hair loss. Barcelona Bioscience absorbs Palma Biotech's liposome and encapsulation technologies.
• Quasfar S.A.minorChannel Partner/ Reseller/ DistributorColombian company partnership for conducting international training courses. First course on Analytical Methods Validation held in Colombia with participation from major pharmaceutical companies.
• European Union (GRAIL Project)coreStrategic or Co-development PartnerGRAIL (Glycerol Biorefinery Approach for Production of High Quality Products of Industrial Value) - EU-funded project involving 15 international partners: 7 companies and 8 universities/research centers. Project converts residual glycerol from biodiésel industry into competitive high-value products.
• EADAcoreStrategic or Co-development PartnerJoint launch of Master's in Pharmaceutical Industry Management combining IUCT's technical/scientific modules with EADA's business management expertise.
• Brainwave Discovery (UK)coreStrategic or Co-development PartnerJoint venture initiated October 2013 with British biotech Brainwave for research on potential drug candidates for Parkinson's disease. Confirmed obtaining of 3 active molecules against Parkinson's.
• Paul AnastascoreOthersPaul Anastas, considered the father of green chemistry and co-creator of the 12 Principles of Green Chemistry, serves as Chairman of Scientific Council for InKemia Green Chemicals USA subsidiary.
• ENAC (Entidad Nacional de Acreditación)coreOthersISO 17025 accreditation body for laboratory quality certification in Spain. InKemia IUCT achieved and expanded this accreditation.
• Ayuntamiento de Parets del VallèsminorOthersPartnership enabling installation of new space focused on training and acceleration of life sciences companies.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• SGS: World-leading testing, inspection, and certification company providing analytical services across life sciences, chemicals, cosmetics, and food. Comparable to InKemia's Technological Services division (ISO 17025-accredited analytical/QC work) though SGS operates a much broader and more global portfolio.
• Lonza Group: Global CDMO providing biopharma manufacturing services including fill-finish and aseptic manufacturing. Comparable in the biopharma services / fill-finish / API manufacturing category, though Lonza is one of the largest players globally and InKemia is sub-scale.
• Charles River Laboratories: Global CRO providing discovery, safety assessment, and manufacturing support to pharma and biotech. Closest peer to InKemia's Open R&D + Innovation services and pre-clinical oncology pipeline, but operates at substantially larger scale and across many more therapeutic areas.
• Eurofins Scientific: Global leader in contract laboratory testing and analytical services for pharmaceutical, chemical, food, and cosmetic industries. Directly comparable in the lab/QC and regulatory testing services InKemia offers through IUCT, though Eurofins operates at vastly greater scale and global breadth.

Direct peers

• Sygnature Discovery: UK-based CRO offering drug discovery services including medicinal chemistry and in vitro biology to pharma clients. Comparable to InKemia's Open R&D + Innovation offering in pharma/medicinal chemistry services, though Sygnature is significantly larger and discovery-only.

Regional players

• Reig Jofre: Spanish pharmaceutical manufacturer listed on the Spanish continuous market, developing and manufacturing prescription drugs, OTC, and sterile injectables. Comparable as a Spanish-headquartered life sciences company serving pharma clients, though operating in finished drug manufacturing rather than R&D services.
• PharmaMar: Spanish biopharmaceutical company developing marine-derived anticancer drugs, headquartered in Madrid and listed on the IBEX. Comparable as a Spanish-listed biotech/life sciences company, though PharmaMar is a product company focused on oncology whereas InKemia is services and green chemistry.
• Laboratorios Rovi: Spanish specialty pharmaceutical company listed on the IBEX, focused on heparin-based products and specialty pharma manufacturing. Comparable as a Spanish-listed pharmaceutical/health sciences company serving similar end markets, though ROVI is in finished dose manufacturing rather than services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/inkemiamab

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InKemia